A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival.

摘要: Background Recent studies have suggested an effect of metformin on mortality for patients with both diabetes and colorectal cancer (crc). However, the literature is contradictory, positive negative effects being identified. We set out to determine respect prognosis in crc patients. Methods After a retrospective chart review treated at Cancer Centre Southeastern Ontario, Kaplan–Meier analyses Cox proportional hazards regression models were used compare overall survival (os) without diabetes. Results identified 1304 centre. No significant differences between diabetic nondiabetic groups observed tumour pathology, extent metastatic disease, time or toxicity chemotherapy, os rate (1-year os: 85.6% vs. 86.4%, p = 0.695; 2-year 73.6% 77.0%, 0.265). In subgroup analysis, taking survived significantly longer than their counterparts other treatments (os group: 91% 1 year; 80.5% 2 years; group treatments, including diet control: 80.6% year, 67.4% years). Multivariate analysis suggests that experience worse ( 0.025). Conclusions Our results suggest diabetes, excluding those metformin, might prognosis. Taking appears association The protective nature needs further evaluation prospective analyses.